Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 9/20 | 0.59 |
| ▸ | CTSB | P07858 | 6/20 | 0.59 |
| ▸ | CTSS | P25774 | 2/20 | 0.57 |
| ▸ | CTSK | P43235 | 1/20 | 0.57 |
| ▸ | TACR1 | P25103 | 2/20 | 0.56 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2601905 | 1.00 | CTSL (0.59) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL31397610 | 1.00 | CTSL (0.59) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL6272041 | 0.96 | CTSL (0.55) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL6272059 | 0.90 | TACR1 (0.59) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL2601895 | 0.90 | TACR1 (0.59) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL16323443 | 0.89 | CTSL (0.57) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL16322636 | 0.89 | CAPN1 (0.60) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL16323306 | 0.89 | CTSL (0.57) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL1037693 | 0.89 | CTSL (0.57) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL16322478 | 0.89 | CTSL (0.57) | CTSLCTSBCTSSCTSKTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116893690-B | Unmanned aerial vehicle evasion attack input data calculation method based on reinforcement learning | 西安爱生技术集团有限公司 | 2024-08-16 | — | — | CN | claimed |
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO., INC. (US) | 2023-05-11 | — | — | US | claimed |
| EP-4149552-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG | Healion Bio, Inc. (US) | 2023-03-22 | — | — | EP | claimed |
| WO-2022072504-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| EP-4597115-A2 | PEPTIDE QUANTITATION ASSAY FOR DIFFERENTIATING FULL-LENGTH HIGH MOLECULAR WEIGHT KININOGEN (HMWK) AND CLEAVED HMWK | Takeda Pharmaceutical Company Limited (JP) | 2025-08-06 | — | — | EP | disclosed |
| EP-4574040-A2 | EVACUATED BLOOD COLLECTION TUBES CONTAINING PROTEASE INHIBITORS FOR THE ASSESSMENT OF CONTACT SYSTEM ACTIVATION | Takeda Pharmaceutical Company Limited (JP) | 2025-06-25 | — | — | EP | disclosed |
| US-20250172567-A1 | PEPTIDE QUANTITATION ASSAY FOR DIFFERENTIATING FULL-LENGTH HIGH MOLECULAR WEIGHT KININOGEN (HMWK) AND CLEAVED HMWK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-05-29 | — | — | US | disclosed |
| EP-3909509-B1 | EVACUATED BLOOD COLLECTION TUBES CONTAINING PROTEASE INHIBITORS FOR THE ASSESSMENT OF CONTACT SYSTEM ACTIVATION | TAKEDA PHARMACEUTICALS CO (JP) | 2025-04-09 | — | — | EP | disclosed |
| EP-3390439-B1 | PEPTIDE QUANTITATION ASSAY FOR DIFFERENTIATING FULL-LENGTH HIGH MOLECULAR WEIGHT KININOGEN (HMWK) AND CLEAVED HMWK | TAKEDA PHARMACEUTICALS CO (JP) | 2025-03-12 | — | — | EP | disclosed |
| US-12135329-B2 | Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-11-05 | — | — | US | disclosed |
| CN-116893690-B | Unmanned aerial vehicle evasion attack input data calculation method based on reinforcement learning | 西安爱生技术集团有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20240190837-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2024-06-13 | — | — | US | disclosed |
| EP-3010532-A1 | MATERIALS FOR POSITIVE CATHEPSIN B MODULATION AND METHODS OF USE FOR TREATING MILD COGNITIVE IMPAIRMENT (MCI), EARLY DEMENTIA, A-SYNUCLEINOPATHY, TRAUMATIC BRAIN INJURY, CARDIOMYOPATHY, EYE DISEASE AND SKIN DAMAGE | University of North Carolina at Pembroke (US) | 2016-04-27 | — | — | EP | disclosed |
| WO-2014204956-A1 | MATERIALS FOR POSITIVE CATHEPSIN B MODULATION AND METHODS OF USE FOR TREATING MILD COGNITIVE IMPAIRMENT (MCI), EARLY DEMENTIA, A-SYNUCLEINOPATHY, TRAUMATIC BRAIN INJURY, CARDIOMYOPATHY, EYE DISEASE AND SKIN DAMAGE | UNIVERSITY OF NORTH CAROLINA AT PEMBROKE (US) | 2014-12-24 | — | — | WO | disclosed |
| EP-0506769-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING RETROVIRAL INFECTIONS | TRANSGENE SA (FR) | 1994-07-27 | — | — | EP | disclosed |
| EP-0506769-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING RETROVIRAL INFECTIONS | TRANSGENE SA (FR) | 1994-07-27 | — | — | EP | disclosed |
| EP-0506769-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING RETROVIRAL INFECTIONS. | TRANSGENE SA (FR) | 1992-10-07 | — | — | EP | disclosed |
| EP-0506769-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING RETROVIRAL INFECTIONS. | TRANSGENE SA (FR) | 1992-10-07 | — | — | EP | disclosed |
| WO-1991008769-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING RETROVIRAL INFECTIONS | TRANSGENE S.A. (FR) | 1991-06-27 | — | — | WO | disclosed |
| WO-1991008769-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING RETROVIRAL INFECTIONS | TRANSGENE S.A. (FR) | 1991-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | CTSV, CTSB, CTSS | CTSL 13/4885CTSB 2/4885CTSS 3/4885 |
| US-20240190837-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | CTSL 1503/4885CTSB 1134/4885CTSS 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.